Journal article · 2007 · Open access

Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO

Atsushi Yoshimori, Junichi Sakai, Satoshi Sunaga, Takanobu Kobayashi, Satoshi Takahashi, Naoyuki Okita, Ryoko Takasawa, Sei‐ichi Tanuma

BMC Pharmacology, 7(1), 8 · Published 27 June 2007 · DOI 10.1186/1471-2210-7-8

Open PDFView at the publisherCite this paper

In brief

“Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO” is a 2007 journal article by Atsushi Yoshimori and 7 co-authors, published in BMC Pharmacology. OpenAlex counts 35 citations as of 22 November 2026. It is open access under a CC BY licence: the full text is free to read at BMC Pharmacology.

Citations
35
Most cited in
2016 (4)
Field-weighted impact
0.89
References
55
Authors
8

Abstract

BACKGROUND: The rational design of peptide-based specific inhibitors of the caspase family members using their X-ray crystallographies is an important strategy for chemical knockdown to define the critical role of each enzyme in apoptosis and inflammation. Recently, we designed a novel potent peptide inhibitor, Ac-DNLD-CHO, for caspase-3 using a new computational screening system named the Amino acid Positional Fitness (APF) method (BMC Pharmacol. 2004, 4:7). Here, we report the specificity of the DNLD sequence against caspase-3 over other major caspase family members that participate in apoptosis by computational docking and site-directed mutagenesis studies. RESULTS: Ac-DNLD-CHO inhibits caspases-3, -7, -8, and -9 activities with Kiapp values of 0.68, 55.7, >200, and >200 nM, respectively. In contrast, a well-known caspase-3 inhibitor, Ac-DEVD-CHO, inhibits all these caspases with similar Kiapp values. The selective recognition of a DNLD sequence by caspase-3 was confirmed by substrate preference studies using fluorometric methylcoumarin-amide (MCA)-fused peptide substrates. The bases for its selectivity and potency were assessed on a notable interaction between the substrate Asn (N) and the caspase-3 residue Ser209 in the S3 subsite and the tight interaction between the substrate Leu (L) and the caspase-3 hydrophobic S2 subsite, respectively, in computational docking studies. Expectedly, the substitution of Ser209 with alanine resulted in loss of the cleavage activity on Ac-DNLD-MCA and had virtually no effect on cleaving Ac-DEVD-MCA. These findings suggest that N and L residues in Ac-DNLD-CHO are the determinants for the selective and potent inhibitory activity against caspase-3. CONCLUSION: On the basis of our results, we conclude that Ac-DNLD-CHO is a reliable, potent and selective inhibitor of caspase-3. The specific inhibitory effect on caspase-3 suggests that this inhibitor could become an important tool for investigations of the biological function of caspase-3. Furthermore, Ac-DNLD-CHO may be an attractive lead compound to generate novel effective non-peptidic pharmaceuticals for caspase-mediated apoptosis diseases, such as neurodegenerative disorders and viral infection diseases.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Yoshimori, A., Sakai, J., Sunaga, S., Kobayashi, T., Takahashi, S., Okita, N., Takasawa, R., & Tanuma, S. (2007). Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO. BMC Pharmacology, 7(1), 8. https://doi.org/10.1186/1471-2210-7-8

MLA 9

Yoshimori, Atsushi, et al. “Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO.” BMC Pharmacology, vol. 7, no. 1, 2007, p. 8. https://doi.org/10.1186/1471-2210-7-8.

Chicago

Yoshimori, Atsushi, Junichi Sakai, Satoshi Sunaga, Takanobu Kobayashi, Satoshi Takahashi, Naoyuki Okita, Ryoko Takasawa, and Sei‐ichi Tanuma. 2007. “Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO.” BMC Pharmacology 7 (1): 8. https://doi.org/10.1186/1471-2210-7-8.

Harvard

Yoshimori, A. et al. (2007) ‘Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO’, BMC Pharmacology, 7(1), p. 8. doi:10.1186/1471-2210-7-8.

IEEE

A. Yoshimori et al., “Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO,” BMC Pharmacology, vol. 7, no. 1, p. 8, 2007, doi: 10.1186/1471-2210-7-8.

BibTeX

@article{yoshimori2007structural,
  title     = {{Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO}},
  author    = {Yoshimori, Atsushi and Sakai, Junichi and Sunaga, Satoshi and Kobayashi, Takanobu and Takahashi, Satoshi and Okita, Naoyuki and Takasawa, Ryoko and Tanuma, Sei‐ichi},
  journal   = {BMC Pharmacology},
  year      = {2007},
  volume    = {7},
  number    = {1},
  pages     = {8},
  doi       = {10.1186/1471-2210-7-8},
  url       = {https://doi.org/10.1186/1471-2210-7-8}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201522
201644
201733
201911
202044
202122
202211
202411
202511
202611

Its field-weighted citation impact is 0.89: it has been cited 0.89 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation

  • caspase-3 inhibitor
  • caspase-7
  • caspase-8
  • caspase-9
  • Ac-DEVD-CHO
  • substrate recognition
  • S2 subsite
  • computational docking

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Yoshimori, A., Sakai, J., Sunaga, S., Kobayashi, T., Takahashi, S., Okita, N., Takasawa, R., & Tanuma, S. (2007). Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO. BMC Pharmacology, 7(1), 8. https://doi.org/10.1186/1471-2210-7-8

How many times has this paper been cited?

35 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at BMC Pharmacology: sign in and open the PDF from this page.

Who wrote this paper?

Atsushi Yoshimori, Junichi Sakai, Satoshi Sunaga, Takanobu Kobayashi, Satoshi Takahashi, Naoyuki Okita, Ryoko Takasawa, Sei‐ichi Tanuma.

What is the DOI of this paper?

10.1186/1471-2210-7-8, permanently at https://doi.org/10.1186/1471-2210-7-8. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.